Stay updated on REGN4336 in Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the REGN4336 in Prostate Cancer Clinical Trial page.

Latest updates to the REGN4336 in Prostate Cancer Clinical Trial page
- Check5 days agoChange DetectedThe study title was updated to state REGN4336 is safe and works alone and in combination with REGN5678, removing Cemiplimab from the combination; the record history also adds several sections (IPDSharing, Eligibility, Outcome Measures, Arms and Interventions, Study Design, Conditions, Study Description, Study Status, and Study Identification) to provide a more complete data representation.SummaryDifference1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThis update reflects a revision/version bump on the ClinicalTrials.gov page interface (from v3.5.2 to v3.5.3), without indicating any changes to the study record details shown in the record history.SummaryDifference0.1%

- Check26 days agoChange DetectedRevision v3.5.2 was added to the record history and Revision v3.5.0 was removed.SummaryDifference0.1%

- Check55 days agoChange DetectedThe record history adds a new revision entry v3.5.0. The prior revision v3.4.3 is removed.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision v3.4.3 was added and revision v3.4.2 was removed from the history.SummaryDifference0.1%

- Check69 days agoChange DetectedContacts/Locations and Study Status were added on 2026-02-27, with 19 new entries added on 2026-02-24; a deletion occurred on 2025-04-09.SummaryDifference0.4%

Stay in the know with updates to REGN4336 in Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REGN4336 in Prostate Cancer Clinical Trial page.